Methamphetamine addiction remains a serious public health problem, yet no approved pharmacotherapies for methamphetamine use disorders (MUD) are available. Considering the important role vesicular monoamine transporter 2 (VMAT2) plays in the mechanism of methamphetamine addiction, our collaborative research focus has been on the discovery of small-molecules that target VMAT2. Extensive structure-activity relationship studies have been carried out.  In this presentation, I will talk about the progress on identifying VMAT2 modulators that specifically decrease methamphetamine’s behavioral effects as potential therapies for MUD.<br/>

Discovery of VMAT2 modulators as potential treatments for methamphetamine use disorders

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.